Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
IBB vs SCHX: how they differ
IBB and SCHX hold 1% of their weight in the same names, and IBB returned more over the year.
iShares Biotechnology ETF and Schwab U.S. Large-Cap ETF.
What they hold in common
By the books each fund has filed, IBB and SCHX hold 1% of their money in the same securities at the same weight.
| Holding | IBB | SCHX |
|---|---|---|
| Amgen, Inc. | 7.84% | 0.27% |
| Gilead Sciences, Inc. | 6.85% | 0.24% |
| Vertex Pharmaceuticals, Inc. | 8.09% | 0.17% |
| Regeneron Pharmaceuticals, Inc. | 4.91% | 0.09% |
| Alnylam Pharmaceuticals, Inc. | 3.12% | 0.06% |
| Natera, Inc. | 2.89% | 0.04% |
| Biogen, Inc. | 2.47% | 0.04% |
| Illumina, Inc. | 2.07% | 0.04% |
| United Therapeutics Corp. | 1.74% | 0.04% |
| Insmed, Inc. | 1.79% | 0.03% |
| Incyte Corp. | 1.75% | 0.02% |
| Moderna, Inc. | 1.99% | 0.02% |
| Only in IBB | Only in SCHX |
|---|---|
| Argenx SE 3.76% | NVIDIA Corp 7.51% |
| Revolution Medicines, Inc. 2.78% | Apple Inc 6.71% |
| BeOne Medicines Ltd. 1.77% | Microsoft Corp 4.89% |
| Roivant Sciences Ltd. 1.43% | Amazon.com Inc 3.87% |
| Ascendis Pharma A/S 1.29% | Alphabet Inc 3.24% |
| Genmab A/S 1.12% | Broadcom Inc 3.10% |
| Ionis Pharmaceuticals, Inc. 1.00% | Alphabet Inc 2.58% |
| Bridgebio Pharma, Inc. 0.98% | Meta Platforms Inc 2.02% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.
| IBB iShares Biotechnology ETF | SCHX Schwab U.S. Large-Cap ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | Schwab |
| What it is | Biotechnology | U.S. Large-Cap |
| Total return, 1 year | +41.5% | +16.8% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +24.0 pts | −0.7 pts |
| Expense ratio | 0.44% | 0.03% |
| Already in the S&P 500 | 35.6% | 94.9% |
| Holdings | 248 | 748 |
IBB in plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
SCHX in plain words
SCHX is an index equity fund tracking the U.S. Large-Cap. Over the year to Sep 11, 2026 it returned +16.8% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.03% a year. By its holdings filed for May 31, 2026, 95% of the fund by weight is stocks the S&P 500 also holds, across 748 positions, with the top ten at 37.3%.
Questions people ask
- Which returned more over the last year, IBB or SCHX?
- In the year to Sep 12, 2026, with distributions reinvested, IBB returned +41.5% and SCHX returned +16.8%, so IBB returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, IBB or SCHX?
- IBB charges 0.44% a year and SCHX charges 0.03%, so SCHX is cheaper. Fees come from each fund's prospectus.
- How much do IBB and SCHX overlap with the S&P 500?
- By their latest filed holdings, 36% of IBB and 95% of SCHX by weight is stocks the S&P 500 already holds. Between the two funds, 1% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, IBB against SCHX, data as of Sep 12, 2026. https://etfiq.com/compare/any/IBB-SCHX Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources